Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 483 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR ΚΑΡΚΙΝΟΣ ΟΡΧΕΩΝ February 10, 2019 Innovative cancer spinouts: 3 new projects get green light August 13, 2021 Addressing Racial Disparities in Cancer Care: “Your Stories” Podcast May 12, 2022 Second- or Third-Line Treatment with Tisotumab Vedotin Results in Greater Efficacy... July 12, 2024 Load more HOT NEWS Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer ¿Los sobrevivientes del cáncer necesitan ser positivos todo el tiempo? Permitirse... Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation... EMA Recommends Granting a Marketing Authorisation for Sugemalimab
